60 rue de Wattignies
Paris 75012
France
33 1 40 26 04 70
https://www.nanobiotix.com
版塊: Healthcare
行業: Biotechnology
全職員工: 102
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Mr. Laurent Levy Ph.D. | Co-Founder, President of the Executive Board & CEO | 765.08k | 無 | 1973 |
Mr. Bart Van Rhijn | CFO & Member of Executive Board | 673.58k | 無 | 1973 |
Ms. Anne-Juliette Hermant M.A. | Chief People Officer & Member of Executive Board | 380.36k | 無 | 1974 |
Dr. Louis Kayitalire M.D. | Chief Medical Officer | 536.73k | 無 | 1958 |
Mr. Earl J. Bergey Ph.d. | Co-Founder | 無 | 無 | 1955 |
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
截至 2024年5月1日 止,Nanobiotix S.A. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中:9;董事會:8;股東權利:7;現金賠償:10。